Abstract
Giant cell arteriitis (GCA) is the most common systemic vasculitis in patients ≥ 50 years. GCA belongs to the group of large vessel vasculitides. Clinical hallmarks of GCA are persistent localized headache, jaw claudication, limb claudication, symptoms of polymyalgia rheumatica, constitutional symptoms and acute visual symptoms. A fast track diagnostic workup and subsequent immediate treatment are crucial to avoid persistent ischemic lesions, particularly blindness. This article reviews the EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice and the 2018 update of the EULAR recommendations for the management of large vessel vasculitis with a focus on GCA and new data on the value of tocilizimab in the treatment of GCA.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
